Follow us on Twitter
twitter icon@FreshPatents


Vaccine Adjuvant patents

      

This page is updated frequently with new Vaccine Adjuvant-related patent applications.




 Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon patent thumbnailPyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
Wherein r1 is hydrogen, methyl or —(ch2)2or3, r2 is methyl or —(ch2)2or4, or r1 and r2, together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents; r3 and r4 are each independently hydrogen or methyl; and n is an integer having a value of 5 or 6, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment or prevention of various disorders, for example the treatment or prevention of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

 Vaccine adjuvants for cytomegalovirus prevention and treatment patent thumbnailVaccine adjuvants for cytomegalovirus prevention and treatment
The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for treating human cytomegalovirus using bacterial cell wall components mdp and tri-dap as vaccine adjuvants.
The Johns Hopkins University


 Plasmid, method and kit thereof for producing heat labile enterotoxin b-subunit patent thumbnailPlasmid, method and kit thereof for producing heat labile enterotoxin b-subunit
The present invention provides a plasmid, method and kit for producing heat labile enterotoxin b-subunit based on a bacillus subtilis expression system. By comparing with the conventional method in the art, the present invention has the advantages of high safety, good yield, and simplified process and is therefore favorable for the commercialization object of heat labile enterotoxin b-subunit in the application of vaccine adjuvant..
Agricultural Technology Research Institute


 Lipid nanoparticle vaccine adjuvants and antigen delivery systems patent thumbnailLipid nanoparticle vaccine adjuvants and antigen delivery systems
The instant invention provides for novel lipid nanoparticle (lnp) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide lnp formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g.
Merck Sharp & Dohme Corp


 Single chain il-12 nucleic acids, polypeptides, and uses thereof patent thumbnailSingle chain il-12 nucleic acids, polypeptides, and uses thereof
The present invention relates to novel single chain interleukin-12 polypeptides. The invention also relates to isolated nucleic acids encoding the single chain interleukin-12 polypeptides, to vectors and cells comprising them, and to their uses, in particular in methods of using single chain il-12 polypeptides, polynucleotides, vectors and cells of the invention for enhancing immune system function, for example as vaccine adjuvants and in the treatment of infections and cancer..
Intrexon Corporation


 Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants patent thumbnailUse of fluorinated cyclic dinucleotides as oral vaccine adjuvants
Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine..
National Research Council Canada


 Use of rapamycin as vaccine adjuvant and preparation method therefor patent thumbnailUse of rapamycin as vaccine adjuvant and preparation method therefor
Disclosed are an immuno-enhancer composition, a use of same as a vaccine adjuvant, and a preparation method therefor. The composition comprises rapamycin and a toll-like receptor agonist-type adjuvant..
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences


 6-amino-purin-8-one compounds patent thumbnail6-amino-purin-8-one compounds
Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants..

 1,2,3-triazole-tethered carbohydrate-di and tri lipidated cysteine conjugates useful as vaccine adjuvants and process for preparation thereof patent thumbnail1,2,3-triazole-tethered carbohydrate-di and tri lipidated cysteine conjugates useful as vaccine adjuvants and process for preparation thereof
The present invention also provides process for preparation of carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles. The carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles as vaccine adjuvants are useful in formulations for therapeutic and prophylactic vaccines against bacterial, viral, protozoan infections and cancer..

 Lipidated immune response modifier compound compositions, formulations, and methods patent thumbnailLipidated immune response modifier compound compositions, formulations, and methods
The compound n-(4-{[4-amino-2-butyl-1h-imidazo[4,5-c]quinolin-1-yl]oxyl}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.. .

An oil-in-water emulsion containing no surfactant and use thereof

The present invention discloses an oil-in-water emulsion containing no surfactant, which comprises a metabolizable oil phase, an aqueous phase and oil-water amphipathic solid particles dispersed in the aqueous phase and having biocompatibility, wherein the oil phase comprises squalene or/and tocol; the aqueous phase is any one selected from the group consisting of purified water, water for injection, glycerine aqueous solution, buffering salts aqueous solution or clinically usable transfusion, or the combination of at least two selected therefrom; the solid particles have an average particle size in a scale of from nanometer to micrometer. The emulsion of the present invention can be used as vaccine adjuvant, drug delivery carrier or sustained/controlled-release carrier, and have the controllable properties.

Vaccine system for vaccine adjuvant

The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced th1 response. The present invention also provides methods of making those compositions and administration of the improved adjuvant compositions.
Vaxform Llc

Composition comprised of antigen linked to a tnf superfamily ligand

The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of tnf superfamily (tnfsf) ligands. The tnfsfs serve as vaccine adjuvants for increasing the immune response to the antigens.

Method for producing beta-hematin crystal comprising step of heating

This invention provides a method of preparing a β-hematin crystal comprising a step of heating, the β-hematin crystal obtained by such method, and a vaccine adjuvant composition containing the β-hematin crystal. The β-hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 μm, and it exhibits main peaks characteristics for angles of diffraction (2θ) of 7.4°, 12.2°, 21.6°, and 24.1° in an x-ray diffraction pattern obtained by powder x-ray diffractometry with cu—kα rays (with each peak including a plus-minus 0.2° diffraction angle)..
Nippon Zenyaku Kogyo Co., Ltd.

Pyrazolopyrimidine compounds

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Design of short oligonucleotides as vaccine adjuvants and therapeutic agents

The invention provides a method of treating a microbial infection in a subject and a method of improving an immune system response in a subject against a disease, condition, infection, or virus thereof, by administering an effective amount of a nucleoside, short oligonucleotide compound or an analog thereof, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer thereof. In addition, the invention provides methods for treating or preventing a viral infection, bacterial infection, parasitic infection, or fungal infection in a subject (such as, a human).
Spring Bank Pharmaceuticals, Inc.

Synthetic tlr4 and tlr7 ligands as vaccine adjuvants

This disclosure relates to compositions and methods useful to augment an immune response and methods and compositions for inducing immunogenicity to influenza antigens.. .
Icahn School Of Medicine At Mount Sinai

Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway

Cyclic-gmp-amp synthase (cgas) and cyclic-gmp-amp (cgamp), including 2′3-cgamp, 2′2-cgamp, 3′2′-cgamp and 3′3′-gamp, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.. .
Board Of Regents, The University Of Texas System

Toll-like receptor 2-agonistic lipopeptides, and making the same

The present disclosure is directed to a novel class of toll-like receptor 2-agonistic (tlr2) lipopeptide compounds having specific structures, and synthetic methods of making the compounds. These compounds provide high potency of agonistic activities with human, other than murine, tlr2, and are useful as vaccine adjuvants.
University Of Kansas

Novel compounds

Wherein r1 is n-c3-6alkyl; r2 is hydrogen or methyl; r3 is hydrogen or c1-6alkyl, and m is an integer having a value of 1 to 4; are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Novel compounds

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Novel compounds

Wherein r1 is n-c3-6alkyl; r2 is hydrogen or methyl; r3 is hydrogen or c1-6alkyl, and m is an integer having a value of 0 to 3; are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof

Disclosed herein are compositions, cells, kits, and methods for inducing an immune response in a subject. The compositions can be used as vaccines or vaccine adjuvants against cancer (e.g., melanoma, glioma, prostate, breast) and infectious diseases (e.g., therapeutic and preventative vaccination for viruses), and can be used in cell-based therapies for preventing and treating disorders such as cancer and infection.
University Of Miami

Pyrazolopyrimidine compounds

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Vaccine adjuvant

Oil-based adjuvant emulsions, immunogenic compositions, and methods of using the same to elicit immunological responses in a subject are provided. The oil-based adjuvants comprise a plant-derived surfactant, such as gum arabic, an aqueous component, and an oil.
University Of Tennessee Research Foundation

Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants

Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsrna together with an anti-influenza vaccine.. .
Hemispherx Biopharma, Inc.

Liposomal vaccine adjuvants and methods of making and using same

A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidicholine (dppc), dipalmitoyl phosphatidylglycerol (dppg), dioleoyl phosphatidylcholine (dopc), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen.. .

Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases

Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Laser-based vaccine adjuvants

The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation.

Vaccine adjuvant composition comprising inulin particles

The present invention provides a composition comprising or consisting of inulin particles for use in the reduction or inhibition of inflammation, and/or for treating or preventing inflammatory disease, in a subject. Also provided is a pharmaceutically acceptable composition comprising: particles of inulin; and a substance comprising or consisting of one or more pathogen-associated molecular patterns (pamps), or an equivalent kit of parts, and methods and uses of the composition and kit for inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine.

Heat-and freeze-stable vaccines and methods of making and using same

A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidlcholine (dppc), dipalmitoyl phosphatidylglycerol (dppg), dioleoyl phosphatidylcholine (dopc), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen.. .

Adjuvanted influenza b virus vaccines for pediatric priming

The influenza b strain is epidemiologically relevant in the pediatric population. Immunogenic priming of children with influenza b vaccine adjuvanted with an oil-in-water emulsion primes an immune response to a booster vaccine comprising influenza b virus antigen from a different strain or lineage, irrespective of whether the booster comprises an adjuvant..

Cationic metal oxides for use as vaccine adjuvants

Adjuvant and immunological vaccine compositions comprising modified, cationic metal oxides are disclosed, including methods of making modified, cationic metal oxides and methods of using the modified metal oxides in vaccine formulations and regimens.. .

Bacterial rnas as vaccine adjuvants

The disclosure features vaccine adjuvants comprising prokaryotic mrna, and methods of vaccination using the adjuvants. More specifically, the disclosure provides a vaccine composition comprising a nonviable immunogen (e.g., heat-killed bacterium), a tumor antigen, or an immunogenic peptide of microbial or mammalian origin, and an adjuvant, wherein adjuvant comprises prokaryotic mrna (e.g., bacterial mrna), as well as the methods of using the vaccine compositions.

Total polysaccharides of radix isatidis and their fractions, and uses thereof as vaccine adjuvants

The present invention pertains to medicinal technical field, relates to a radix isatidis total polysaccharide and fractions thereof and their uses as vaccine adjuvant. Specifically, it relates to a radix isatidis total polysaccharide as well as neutral polysaccharide fraction and acidic polysaccharide fraction extracted from chinese medicinal material radix isatidis, and to their uses as vaccine adjuvant or uses in manufacture of vaccine composition.

Polychlorinated biphenyls and squalene-containing adjuvants

When using squalene in a vaccine adjuvant, there is a possibility of contamination with polychlorinated biphenyls (pcbs). Environmental exposure to pcbs may adversely affect children's immune responses to routine vaccinations.

Vaccine adjuvant, vaccine composition and preparing a vaccine adjuvant

The disclosure provides a vaccine adjuvant, including a polysaccharide derived from antrodia camphorata (also named antrodia cinnamomea or taiwanofungus camphoratus) fruiting body, wherein the molecular weight of the polysaccharide is greater than 100 k da. Furthermore, the polysaccharide is obtained by an extraction process, and the extraction process includes: (a) adding powder of the antrodia camphorata fruiting body into water to form a mixture; (b) heating the mixture under reflux; (c) after step (b), removing an insoluble matter from the mixture; (d) after step (c), adding ethanol into the mixture to perform a precipitating step and obtain a precipitate; and (e) performing an isolating step to the precipitate to obtain a fraction the molecular weight of which is greater than 100 k da of the precipitate..

Use of cyclodextrins in diets, water or vaccine adjuvants to boost the immune system of fish

The present disclosure describes compositions containing cyclodextrin and methods of using cyclodextrins to stimulate or enhance the immune system and response in fish. Methods of enhancing the efficacy of a fish vaccine by administering cyclodextrin to the fish are also described..

Adjuvant for the preparation of vaccine compositions intended for the prevention of coccidiosis

A vaccine adjuvant which, based on the 100% mass thereof, includes between 10% and 95% of a mineral oil containing: between 0.05 mass-% and 10 mass-% hydrocarbon chains having less than 16 carbon atoms, and between 0.05 mass-% and 5 mass-% hydrocarbon chains having more than 28 carbon atoms. In addition, the adjuvant has a p/n ratio, corresponding to the ratio of the mass quantity of the paraffinic hydrocarbon chains to the mass quantity of the naphthenic hydrocarbon chains, of between 2.5 and 3, the adjuvant being intended for the production of a vaccine composition to prevent coccidiosis..

Vaccine adjuvants from self-assembling peptides

Pharmaceutical or veterinary compositions, vaccine systems, methods, and kits for treating or protecting a subject from a condition using peptide-based adjuvants are provided. The peptide adjuvants comprise a peptide having a hydrophobic region, a turning region, and a hydrophilic region.

Novel compounds

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Vaccine adjuvant

A method for enhancing a vaccine therapy effect by a vaccine composition. The method including a step of implanting β-tricalcium phosphate in an inside of a body of a subject, and a step of administering the vaccine composition to the subject at the same time with or before or after the implanting step..

Novel adenine derivatives

N is an integer having a value of 1 to 6; het is a 6-membered saturated heterocycle containing one nitrogen atom wherein het is attached to the —(ch2)n— moiety at any carbon atom of the heterocycle; r3 is hydrogen, c1-8alkyl, or c3-7cycloalkylc0-6alkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants..



Vaccine Adjuvant topics:
  • Vaccine Adjuvant
  • Immune Response
  • Nucleic Acid
  • Recombinant
  • Polypeptide
  • Modulation
  • Immunogenic
  • Seroconversion
  • Influenza Vaccine
  • Persistence
  • Antibody Titer
  • Salmonella
  • Vaccination
  • Hepatitis B
  • Hepatitis B Vaccine


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Vaccine Adjuvant for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine Adjuvant with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2451

    file did exist - 2285

    0 - 1 - 44